Vitrolife AB (publ)

Vitrolife AB (publ)
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Contacts

Bronwyn Brophy O'Connor

CEO

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
http://www.vitrolifegroup.com

Patrik Tolf

CFO

Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
+46 31 766 90 21
http://www.vitrolifegroup.com

Vitrolife AB
+46 (0)31 721 80 00
+46 (0)31 721 80 99
http://www.vitrolifegroup.com
info@vitrolife.com

Allotment of acquisition cost decided by the Swedish Tax Agency

Thu, Dec 20, 2012 15:00 CET

In connection with Vitrolife’s distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.Further information can be found on the Swedish Tax Agency’s website and at www.vitrolife.com/en/Corporate/

Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012

Thu, Oct 04, 2012 08:30 CET

Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8. In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website. The company description (in Swedish) is also available at Vitrolife’s webpage www.vitrolife.com /corporate. October 4, 2012

Information regarding the distribution of Xvivo Perfusion AB

Mon, Sep 24, 2012 16:35 CET

In accordance with the resolution adopted by the Extraordinary General Meeting of shareholders held on September 24, Vitrolife’s transplantation business, which is run in the subsidiary Xvivo Perfusion AB (”Xvivo”) and its subsidiaries, will be spun off to the shareholders through distribution of the shares in Xvivo in accordance with “Lex Asea”.The resolution means that the Vitrolife shareholders will automatically receive one share in Xvivo for each share that they own in Vitrolife. The distribution will not result in any tax effect for present Vitrolife shareholders as long as they

Notice of Extraordinary General Meeting of Vitrolife AB (publ)

Fri, Aug 31, 2012 12:00 CET

The Extraordinary General Meeting of Vitrolife AB (publ) will take place on Monday September 24, 2012, at 3 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Extraordinary General Meeting shall be given no later than Tuesday, September 18, 2012, at 12 noon.Shareholders wishing to participate at the Extraordinary General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99 or by e-mail aahlqvist@vitrolife.com. Name/

There are no items matching the current filter

There are no more items matching the current filter

Share